The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLC
ABSTRACT Background Currently, the most effective oral targeted therapies for NSCLC in clinical practice are EGFR‐TKIs. However, acquired drug resistance often leads to tumor progression and recurrence. EGFR overexpression and activation of its downstream pathways are primary contributors to both mu...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2025-02-01
|
| Col·lecció: | Cancer Medicine |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/cam4.70643 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|